Over the last 12 months, three Cartesian Growth Corp III executives and directors added shares with their own money, about $15.2 million in total, and none of them sold.
Biggest single buyer: Yu Peter, CEO, with roughly $6.9 million. Notably, at least one C-suite executive was among the buyers.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Yu Peter | CEO | Buy | 6,089 | $10.38 | $63K | SEC |
| Apr 17, 2026 | CGC III Sponsor LLC | CEO | Buy | 100,000 | $10.33 | $1.0M | SEC |
| Apr 17, 2026 | CGC III Sponsor LLC | CEO | Buy | 100,000 | $10.32 | $1.0M | SEC |
| Apr 8, 2026 | Yu Peter | CEO | Buy | 100,000 | $10.31 | $1.0M | SEC |
| Apr 8, 2026 | Yu Peter | CEO | Buy | 100,000 | $10.31 | $1.0M | SEC |
| Apr 8, 2026 | Yu Peter | CEO | Buy | 100,000 | $10.30 | $1.0M | SEC |
| Apr 2, 2026 | Yu Peter | CEO | Buy | 671,000 | $10.30 | $6.9M | SEC |
| Apr 2, 2026 | Yu Peter | CEO | Buy | 300,000 | $10.28 | $3.1M | SEC |
In the last 12 months Cartesian Growth Corp III insiders made open-market purchases worth about $15.2 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CGCT was filed on 2026-05-22.
No congressional trades in CGCT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).